Dr. Jun Zhang 张军
Chief Physician
Department of Breast Oncology I, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of breast cancer, including mastectomy, breast-conserving surgery, sentinel lymph node biopsy, and minimally invasive removal of benign tumors. Expertise in endoscopic breast reconstruction and oncoplastic surgery.
Dr. Zhang is a Chief Physician and MD at Tianjin Medical University Cancer Institute & Hospital. As a master’s supervisor, Dr. Zhang has treated over 6,000 patients and performed more than 5,800 surgeries, including over 200 complex cases. Clinical focus includes breast cancer surgery, endoscopic reconstruction, and oncoplastic procedures.
Professional roles
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association (Young Expert)
- Member, Metastatic Tumor Treatment Society, China Medical Promotion Association
- Standing Committee Member, Virtual Simulation Technology and Precision Medicine Professional Committee
- Member, Chemotherapy Group, Oncology Branch, Tianjin Medical Association
Name order: in Chinese the family name comes first (Zhang Jun). Papers usually list the name as Jun Zhang or Zhang J.
Selected publications
56 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (first author): Mesh-free prepectoral breast reconstruction: a safe and effective alternative. PubMed 42245716
- Biochem Biophys Res Commun, 2026 (first author): Characterization of the SHP2-Fumosorinone interaction using biochemical and computational approaches. PubMed 41506133
- Front Oncol, 2024 (first author): Comparison of outcomes following prepectoral and subpectoral implants for breast reconstruction in patients with breast cancer. PubMed 39839769
- Cell Death Dis, 2024 (senior author): FATS inhibits the Wnt pathway and induces apoptosis through degradation of MYH9 and enhances sensitivity to paclitaxel in breast cancer. PubMed 39550407
- Cancer Biol Med, 2021 (first author): Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer. PubMed 33628588
- Thorac Cancer, 2020 (first author): GPX8 promotes migration and invasion by regulating epithelial characteristics in non-small cell lung cancer. PubMed 32975378
- Cell Death Dis, 2020 (senior author): FATS regulates polyamine biosynthesis by promoting ODC degradation in an ERβ-dependent manner in non-small-cell lung cancer. PubMed 33037185
- Cancer Manag Res, 2019 (first author): Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma. PubMed 31118795
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion